Expired CME Article

Influenza Therapy

Authors: James W. Myers, MD

Abstract

New agents for the treatment of influenza have changed the therapeutic approach for individuals with this age-old disease. The exact role of these antimicrobial agents remains to be defined, but they seem to be effective in shortening the duration of symptoms in most patients. They are more expensive than the older agents, however, which still play a role in the management of influenza infection. Vaccination remains the most important measure to combat this potentially deadly disease.

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1. Hay AJ. Amantadine and rimantadine: Mechanisms, in Richman DD (ed): Antiviral Drug Resistance. New York, John Wiley & Sons, 1996, pp 43–58.
 
2. Pinto LH, Holsinger LJ, Lamb RA. Influenza virus M2 protein has ion channel activity. Cell 1992; 69: 517–528.
 
3. Englund JA, Champlin RE, Wyde PR, et al. Common emergence of amantadine- and rimantadine-resistant influenza A viruses in symptomatic immunocompromised adults. Clin Infect Dis 1998; 26: 1418–1424.
 
4. Hayden FG, Belshe RB, Clover RD, et al. Emergence and apparent transmission of rimantadine-resistant influenza A virus in families. N Engl J Med 1989; 321: 1696–1702.
 
5. Mast EE, Harmon MW, Gravenstein S, et al. Emergence and possible transmission of amantadine-resistant viruses during nursing home outbreaks of influenza A (H3N2). Am J Epidemiol 1991; 134: 988–997.
 
6. Aoki FY, Sitar DS. Clinical pharmacokinetics of amantadine hydrochloride. Clin Pharmacokinet 1988; 14: 35–51.
 
7. Horadam VW, Sharp JG, Smilack JD, et al. Pharmacokinetics of amantadine hydrochloride in subjects with normal and impaired renal function. Ann Intern Med 1981; 94: 454–458.
 
8. Dolin R, Reichman RC, Madore HP, et al. A controlled trial of amantadine and rimantadine in the prophylaxis of influenza A infection. N Engl J Med 1982; 307: 580–584.
 
9. Arden NH, Patriarca PA, Fasano MB, et al. The roles of vaccination and amantadine prophylaxis in controlling an outbreak of influenza A (H3N2) in a nursing home. Arch Intern Med 1988; 148: 865–868.
 
10. Atkinson WL, Arden NH, Patriarca PA, et al. Amantadine prophylaxis during an institutional outbreak of type A (H1N1) influenza. Arch Intern Med 1986; 146: 1751–1756.
 
11. Galbraith AW, Oxford JS, Schild GC, et al. Protective effect of 1-adamantanamine hydrochloride on influenza A2 infections in the family environment: A controlled double-blind study. Lancet 1969; 2: 1026–1028.
 
12. Hayden FG, Sperber SJ, Belshe RB, et al. Recovery of drug-resistant influenza A virus during therapeutic use of rimantadine. Antimicrob Agents Chemother 1991; 35: 1741–1747.
 
13. Belshe RB, Burk B, Newman F, et al. Resistance of influenza A virus to amantadine and rimantadine: Results of one decade of surveillance. J Infect Dis 1989; 159: 430–435.
 
14. Bean WJ, Threlkeld SC, Webster RG. Biologic potential of amantadine-resistant influenza A virus in an avian model. J Infect Dis 1989; 159: 1050–1056.
 
15. Degelau J, Somani SK, Cooper SL, et al. Amantadine-resistant influenza A in a nursing facility. Arch Intern Med 1992; 152: 390–392.
 
16. Younkin SW, Betts RF, Roth FK, et al. Reduction in fever and symptoms in young adults with influenza A/Brazil/78 H1N1 infection after treatment with aspirin or amantadine. Antimicrob Agents Chemother 1983; 23: 577–582.
 
17. Little JW, Hall WJ, Douglas RG Jr, et al. Airway hyperreactivity and peripheral airway dysfunction in influenza A infection. Am Rev Respir Dis 1978; 118: 295–303.
 
18. Wills RJ, Rodriguez LC, Choma N, et al. Influence of a meal on the bioavailability of rimantadine HCl. J Clin Pharmacol 1987; 27: 821–823.
 
19. Wills RJ, Belshe R, Tomlinsin D, et al. Pharmacokinetics of rimantadine hydrochloride in patients with chronic liver disease. Clin Pharmacol Ther 1987; 42: 449–454.
 
20. Crawford SA, Clover RD, Abell TD, et al. Rimantadine prophylaxis in children: A follow-up study. Pediatr Infect Dis J 1988; 7: 379–383.
 
21. Brady MT, Sears SD, Pacini DL, et al. Safety and prophylactic efficacy of low-dose rimantadine in adults during an influenza A epidemic. Antimicrob Agents Chemother 1990; 34: 1633–1636.
 
22. Govorkova EA, Leneva IA, Goloubeva OG, et al. Comparison of efficacies of RWJ-270201, zanamivir, and oseltamivir against H5N1, H9N2, and other avian influenza viruses. Antimicrob Agents Chemother 2001; 45: 2723–2732.
 
23. Smee DF, Huffman JH, Morrison AC, et al. Cyclopentane neuraminidase inhibitors with potent in vitro anti-influenza virus activities. Antimicrob Agents Chemother 2001; 45: 743–748.
 
24. Carr J, Ives J, Kelly L, et al. Influenza virus carrying neuraminidase with reduced sensitivity to oseltamivir carboxylate has altered properties in vitro and is compromised for infectivity and replicative ability in vivo. Antiviral Res 2002; 54: 79–88.
 
25. Ives JA, Carr JA, Mendel DB, et al. The H274Y mutation in the influenza A/H1N1 neuraminidase active site following oseltamivir phosphate treatment leave virus severely compromised both in vitro and in vivo. Antiviral Res 2002; 55: 307–317.
 
26. Roche Laboratories. Tamiflu (oseltamivir phosphate) capsules [package insert]. Nutley, NJ, Roche Laboratories, Inc., 2000.
 
27. Hayden FG, Treanor JJ, Fritz RS, et al. Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: Randomized controlled trials for prevention and treatment. JAMA 1999; 282: 1240–1246.
 
28. Treanor JJ, Hayden FG, Vrooman PS, et al. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: A randomized controlled trial—US Oral Neuraminidase Study Group. JAMA 2000; 283: 1016–1024.
 
29. Gubareva LV, Bethell R, Hart GJ, et al. Characterization of mutants of influenza A virus selected with the neuraminidase inhibitor 4-guanidino-Neu5Ac2en. J Virol 1996; 70: 1818–1827.
 
30. McKimm-Breschkin JL, Sahasrabudhe A, Blick TJ, et al. Mutations in a conserved residue in the influenza virus neuraminidase active site decreases sensitivity to Neu5Ac2en-derived inhibitors. J Virol 1998; 72: 2456–2462.
 
31. Gubareva LV, Robinson MJ, Bethell RC, et al. Catalytic and framework mutations in the neuraminidase active site of influenza viruses that are resistant to 4-guanidino-Neu5Ac2en. J Virol 1997; 71: 3385–3390.
 
32. Center for Drug Evaluation and Research, Food and Drug Administration, U.S. Department of Health and Human Services. Safe and Appropriate Use of Influenza Drugs (Public Health Advisory). Bethesda, MD, U.S. Food and Drug Administration, January 12, 2000. Available at:http://www.fda.gov/cder/drug/advisory/influenza.htm. Accessed June 20, 2003.
 
33. Hayden FG, Osterhaus AD, Treanor JJ, et al. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections: GG167 Influenza Study Group. N Engl J Med 1997; 337: 874–880.
 
34. Couch RB. Prevention and treatment of influenza. N Engl J Med 2000; 343: 1778–1787.
 
35. Kaiser L, Keene ON, Hammond JM, et al. Impact of zanamivir on antibiotic use for respiratory events following acute influenza in adolescents and adults. Arch Intern Med 2000; 160: 3234–3240.
 
36. Lalezari J, Campion K, Keene O, et al. Zanamivir for the treatment of influenza A and B infection in high-risk patients: A pooled analysis of randomized controlled trials. Arch Intern Med 2001; 161: 212–217.
37. Monto AS, Robinson DP, Herlocher ML, et al. Zanamivir in the prevention of influenza among healthy adults: A randomized controlled trial. JAMA 1999; 282: 31–35.
 
38. Hayden FG, Gubareva LV, Monto AS, et al. Inhaled zanamivir for the prevention of influenza in families: Zanamivir Family Study Group. N Engl J Med 2000; 343: 1282–1289.
 
39. Peters PH Jr, Gravenstein S, Norwood P, et al. Long-term use of oseltamivir for the prophylaxis of influenza in a vaccinated frail older population. J Am Geriatr Soc 2001; 49: 1025–1031.
 
40. Parker R, Loewen N, Skowronski D. Experience with oseltamivir in the control of a nursing home influenza B outbreak [in English, French]. Can Commun Dis Rep 2001; 27: 37–40.
 
41. Sturpe D, Seaton TL. Is oral oseltamivir safe and effective for the prevention of influenza and its complications in frail elderly long-term care residents who have received influenza vaccine? J Fam Pract 2002; 51: 87.
 
42. Kingston BJ, Wright CV Jr. Influenza in the nursing home. Am Fam Physician 2002; 65: 72, 75–78.
 
43. Welliver R, Monto AS, Carewicz O, et al. Effectiveness of oseltamivir in preventing influenza in household contacts: A randomized controlled trial. JAMA 2001; 285: 748–754.
 
44. Cifu A, Levinson W. Influenza. JAMA 2000; 284: 2847–2849.
 
45. Wright P. Influenza in the family. N Engl J Med 2000; 343: 1331–1332(editorial).
 
46. Armstrong EP, Khan ZM, Perry AS, et al. The cost effectiveness of zanamivir and oseltamivir for influenza treatment. Formulary 2000; 35: 979–989.
 
47. Sintchenko V, Gilbert GL, Coiera E, et al. Treat or test first? Decision analysis of empirical antiviral treatment of influenza virus infection versus treatment based on rapid test results. J Clin Virol 2002; 25: 15–21.